{"groups":[{"description":"Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60-240 minutes on days 1-3, dexamethasone PO on days 1-4, and filgrastim SC beginning on day 5 and continuing until peripheral blood stem cell collection is complete. Patients undergo leukapheresis daily for a minimum of 3 days or until \\> 5 x 10\\^6 CD34+/kg has been collected.\n\n.\n\nbendamustine hydrochloride: Given IV\n\ndexamethasone: Given PO\n\nfilgrastim: Given SC\n\nleukapheresis: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nflow cytometry: Correlative studies\n\netoposide: Given IV","id":"FG000","title":"Treatment (Chemotherapy and Colony-stimulating Factor)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"43"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"34"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}